Literature DB >> 33856288

Effects of electret coating technology on coronary stent thrombogenicity.

M Urooj Zafar1, Jose Javier Bravo-Cordero2, Sergi Torramade-Moix3, Gines Escolar1,3, Didac Jerez-Dolz3, Eli I Lev4, Juan Jose Badimon1.   

Abstract

Stent thrombosis (ST) is a catastrophic event and efforts to reduce its incidence by altering blood-stent interactions are longstanding. A new electret coating technology that produces long-lasting negative charge on stent surface could make them intrinsically resistant to thrombosis. We assessed the thrombogenicity of stents using an annular perfusion model with confocal microscopy, and determined the efficacy of electret coating technology to confer thrombo-resistant properties to standard stents. Using an annular perfusion chamber, Bare Metal Stent (BMS), standard uncoated DES (DES), and Electret-coated DES (e-DES) were exposed to human blood under arterial flow conditions. Deposits of fibrinogen and platelets on the stent surface were analyzed using immunofluorescence staining and confocal microscopy. Surface coverage by fibrinogen and platelets and the deposit/aggregate size were quantified using computerized morphometric analysis. The experimental methodology produced consistent, quantifiable results. Area of stent surface covered by fibrinogen and platelets and the average size of the deposits/aggregates were lowest for e-DES and highest on BMS, with DES in the middle. The size of fibrinogen-deposits showed no differences between the stents. The testing methodology used in our study successfully demonstrated that electret coating confers significant antithrombotic property to DES stents. These findings warrant confirmation in a larger study.

Entities:  

Keywords:  Electret; platelet; stent; stent coating; thrombosis

Mesh:

Year:  2021        PMID: 33856288      PMCID: PMC8759110          DOI: 10.1080/09537104.2021.1912313

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  38 in total

1.  Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.

Authors:  Kaare H Bønaa; Jan Mannsverk; Rune Wiseth; Lars Aaberge; Yngvar Myreng; Ottar Nygård; Dennis W Nilsen; Nils-Einar Kløw; Michael Uchto; Thor Trovik; Bjørn Bendz; Sindre Stavnes; Reidar Bjørnerheim; Alf-Inge Larsen; Morten Slette; Terje Steigen; Ole J Jakobsen; Øyvind Bleie; Eigil Fossum; Tove A Hanssen; Øystein Dahl-Eriksen; Inger Njølstad; Knut Rasmussen; Tom Wilsgaard; Jan E Nordrehaug
Journal:  N Engl J Med       Date:  2016-08-29       Impact factor: 91.245

2.  Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.

Authors:  Tomohisa Tada; Robert A Byrne; Iva Simunovic; Lamin A King; Salvatore Cassese; Michael Joner; Massimiliano Fusaro; Simon Schneider; Stefanie Schulz; Tareq Ibrahim; Ilka Ott; Steffen Massberg; Karl-Ludwig Laugwitz; Adnan Kastrati
Journal:  JACC Cardiovasc Interv       Date:  2013-12       Impact factor: 11.195

3.  Role of surface charge of the blood vessel wall, blood cells, and prosthetic materials in intravascular thrombosis.

Authors:  S Srinivasan; P N Sawyer
Journal:  J Colloid Interface Sci       Date:  1970-03       Impact factor: 8.128

4.  A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components.

Authors:  K S Sakariassen; P A Aarts; P G de Groot; W P Houdijk; J J Sixma
Journal:  J Lab Clin Med       Date:  1983-10

Review 5.  The relationship between surface charge (potential characteristics) of the vascular interface and thrombosis.

Authors:  P N Sawyer
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

6.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.

Authors:  Roxana Mehran; Usman Baber; Philippe Gabriel Steg; Cono Ariti; Giora Weisz; Bernhard Witzenbichler; Timothy D Henry; Annapoorna S Kini; Thomas Stuckey; David J Cohen; Peter B Berger; Ioannis Iakovou; George Dangas; Ron Waksman; David Antoniucci; Samantha Sartori; Mitchell W Krucoff; James B Hermiller; Fayaz Shawl; C Michael Gibson; Alaide Chieffo; Maria Alu; David J Moliterno; Antonio Colombo; Stuart Pocock
Journal:  Lancet       Date:  2013-09-01       Impact factor: 79.321

7.  Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry.

Authors:  Jochem W van Werkum; Antonius A Heestermans; A Carla Zomer; Johannes C Kelder; Maarten-Jan Suttorp; Benno J Rensing; Jacques J Koolen; B R Guus Brueren; Jan-Henk E Dambrink; Raymond W Hautvast; Freek W Verheugt; Jurriën M ten Berg
Journal:  J Am Coll Cardiol       Date:  2009-04-21       Impact factor: 24.094

8.  In vitro platelet interactions in whole human blood exposed to biomaterial surfaces: insights on blood compatibility.

Authors:  C L Haycox; B D Ratner
Journal:  J Biomed Mater Res       Date:  1993-09

9.  Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents.

Authors:  Christoph Varenhorst; Martin Lindholm; Giovanna Sarno; Göran Olivecrona; Ulf Jensen; Johan Nilsson; Jörg Carlsson; Stefan James; Bo Lagerqvist
Journal:  Clin Res Cardiol       Date:  2018-04-17       Impact factor: 5.460

Review 10.  Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014.

Authors:  Robert A Byrne; Michael Joner; Adnan Kastrati
Journal:  Eur Heart J       Date:  2015-09-28       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.